Current and historical daily PE Ratio for Redhill Biopharma Ltd (
) from 2013 to May 16 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Redhill Biopharma stock (RDHL) PE ratio as of May 16 2024 is 0.
More Details
Redhill Biopharma Ltd (RDHL) PE Ratio (TTM) Chart
Redhill Biopharma Ltd (RDHL) PE Ratio (TTM) Historical Data
View and export this data going back to 2013. Start your Free Trial
Total 1230
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Redhill Biopharma PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-16 | 0.0 | 2024-03-13 | 0.0 |
| 2024-05-15 | 0.0 | 2024-03-12 | 0.0 |
| 2024-05-14 | 0.0 | 2024-03-11 | 0.0 |
| 2024-05-13 | 0.0 | 2024-03-08 | 0.0 |
| 2024-05-10 | 0.0 | 2024-03-07 | 0.0 |
| 2024-05-09 | 0.0 | 2024-03-06 | 0.0 |
| 2024-05-08 | 0.0 | 2024-03-05 | 0.0 |
| 2024-05-07 | 0.0 | 2024-03-04 | 0.0 |
| 2024-05-06 | 0.0 | 2024-03-01 | 0.0 |
| 2024-05-03 | 0.0 | 2024-02-29 | 0.0 |
| 2024-05-02 | 0.0 | 2024-02-28 | 0.0 |
| 2024-05-01 | 0.0 | 2024-02-27 | 0.0 |
| 2024-04-30 | 0.0 | 2024-02-26 | 0.0 |
| 2024-04-29 | 0.0 | 2024-02-23 | 0.0 |
| 2024-04-26 | 0.0 | 2024-02-22 | 0.0 |
| 2024-04-25 | 0.0 | 2024-02-21 | 0.0 |
| 2024-04-24 | 0.0 | 2024-02-20 | 0.0 |
| 2024-04-23 | 0.0 | 2024-02-16 | 0.0 |
| 2024-04-22 | 0.0 | 2024-02-15 | 0.0 |
| 2024-04-19 | 0.0 | 2024-02-14 | 0.0 |
| 2024-04-18 | 0.0 | 2024-02-13 | 0.0 |
| 2024-04-17 | 0.0 | 2024-02-12 | 0.0 |
| 2024-04-16 | 0.0 | 2024-02-09 | 0.0 |
| 2024-04-15 | 0.0 | 2024-02-08 | 0.0 |
| 2024-04-12 | 0.0 | 2024-02-07 | 0.0 |
| 2024-04-11 | 0.0 | 2024-02-06 | 0.0 |
| 2024-04-10 | 0.0 | 2024-02-05 | 0.0 |
| 2024-04-09 | 0.0 | 2024-02-02 | 0.0 |
| 2024-04-08 | 0.0 | 2024-02-01 | 0.0 |
| 2024-04-05 | 0.0 | 2024-01-31 | 0.0 |
| 2024-04-04 | 0.0 | 2024-01-30 | 0.0 |
| 2024-04-03 | 0.0 | 2024-01-29 | 0.0 |
| 2024-04-02 | 0.0 | 2024-01-26 | 0.0 |
| 2024-04-01 | 0.0 | 2024-01-25 | 0.0 |
| 2024-03-28 | 0.0 | 2024-01-24 | 0.1 |
| 2024-03-27 | 0.0 | 2024-01-23 | 0.0 |
| 2024-03-26 | 0.0 | 2024-01-22 | 0.1 |
| 2024-03-25 | 0.0 | 2024-01-19 | 0.1 |
| 2024-03-22 | 0.0 | 2024-01-18 | 0.1 |
| 2024-03-21 | 0.0 | 2024-01-17 | 0.1 |
| 2024-03-20 | 0.0 | 2024-01-16 | 0.1 |
| 2024-03-19 | 0.0 | 2024-01-12 | 0.1 |
| 2024-03-18 | 0.0 | 2024-01-11 | 0.1 |
| 2024-03-15 | 0.0 | 2024-01-10 | 0.1 |
| 2024-03-14 | 0.0 | 2024-01-09 | 0.1 |
Redhill Biopharma Ltd (RDHL) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Redhill Biopharma Ltd
NAICS : 325412
ISIN : US7574681034
Share Class Description:
RDHL: ADRDescription
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers